Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 1050 of 3284 entries
View as:

Study to Assess Safety and Tolerability of AZD2171 After Multiple Doses in Patients With Advanced Prostate Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00502164 Org: User:
Start: 03/31/04 End: - Due: -

To Investigate Safety, Tolerability and Pharmacokinetics of TC-5214 in Healthy Male Japanese Subjects

Phase: N/A Priority: Normal
NCT ID: NCT01175564 Org: User:
Start: 07/31/10 End: 09/30/10 Due: 09/30/11

AZD5423 Single Ascending Dose Study

Phase: N/A Priority: Normal
NCT ID: NCT00963183 Org: User:
Start: 08/31/09 End: 11/30/09 Due: 11/30/10

Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06380751 Org: User:
Start: 08/01/24 End: 10/18/30 Due: 10/18/31

Open-label Extension Study of Brazikumab in Crohn's Disease

Phase: N/A Priority: Normal
NCT ID: NCT03961815 Org: User:
Start: 01/06/20 End: 09/19/23 Due: 09/19/24

A Study Evaluating the Effect of Inhaled PT007(AS MDI) Versus Placebo MDI and Ventolin Evohaler on Lung Function in Adult Participants With Asthma

Phase: N/A Priority: Normal
NCT ID: NCT06644924 Org: User:
Start: 02/10/25 End: 06/04/25 Due: 06/04/26

A Phase Ib Study of AZD5462 on Top of Dapagliflozin in Participants With Heart Failure and Moderate Renal Impairment

Phase: N/A Priority: Normal
NCT ID: NCT06639087 Org: User:
Start: 09/27/24 End: 05/29/25 Due: 05/29/26

Efficacy, Safety, and Tolerability of Once Daily Oral Administration of AZD5004 Versus Placebo for 26 Weeks in Adults With Type 2 Diabetes Mellitus.

Phase: N/A Priority: Normal
NCT ID: NCT06579105 Org: User:
Start: 10/08/24 End: 12/19/25 Due: 12/19/26

A Pharmacokinetic (PK) and Pharmacodynamic (PD) Dose-ranging Phase II Study of Ticagrelor in Paediatric Patients With Sickle Cell Disease

Phase: N/A Priority: Normal
NCT ID: NCT02214121 Org: User:
Start: 09/11/14 End: 02/27/17 Due: 02/27/18

Retention Rate of Acalabrutinib in a Non-interventional Setting

Phase: N/A Priority: Normal
NCT ID: NCT05645172 Org: User:
Start: 12/12/22 End: 10/15/26 Due: 10/15/27

Study of AZD2811 + Durvalumab in ES-SCLC

Phase: N/A Priority: Normal
NCT ID: NCT04745689 Org: User:
Start: 02/23/21 End: 12/01/25 Due: 12/01/26

Phase 2 Study of Disease Risk Mutation-Guided Finite Acalabrutinib+Venetoclax for Relapsed CLL Post-1L Finite cBTKi+BCL2i ± Obinutuzumab

Phase: N/A Priority: Normal
NCT ID: NCT07024706 Org: User:
Start: 09/30/25 End: 11/30/32 Due: 11/30/33

A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4248 in Healthy Participants and Participants With Chronic Kidney Disease and Type 2 Diabetes and to Assess Home Measurements of Creatinine in a Non Interventional Cohort

Phase: N/A Priority: Normal
NCT ID: NCT07024823 Org: User:
Start: 06/10/25 End: 05/01/26 Due: 05/01/27

Efficacy, Safety and Tolerability of Aclidinium Bromide/Formoterol Fumarate Compared With Aclidinium Bromide and Formoterol Fumarate in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

Phase: N/A Priority: Normal
NCT ID: NCT01437397 Org: User:
Start: 09/30/11 End: 02/28/13 Due: 02/28/14

A Phase IIIB Study to Evaluate the Use of Capivasertib in Combination With Fulvestrant in Patients With Advanced Breast Cancer Who Have Relapsed/Progressed on ET and CDK4/6 Inhibitor Reflecting Real World Clinical Practice in Spain

Phase: N/A Priority: Normal
NCT ID: NCT06764186 Org: User:
Start: 01/07/25 End: 12/31/27 Due: 12/31/28

A Study of AZD0486 Plus Rituximab in Previously Untreated Follicular Lymphoma Patients

Phase: N/A Priority: Normal
NCT ID: NCT06549595 Org: User:
Start: 08/07/24 End: 11/26/31 Due: 11/26/32

A Dose Range-Finding Study to Assess the Efficacy and Safety of Multiple Dose Levels of AZD8630 in Adults With Uncontrolled Asthma at Risk of Exacerbations

Phase: N/A Priority: Normal
NCT ID: NCT06529419 Org: User:
Start: 08/30/24 End: 04/06/26 Due: 04/06/27

A Study to Investigate the Effect on Lung Function of BDA Formulated With a New Propellant (HFO) Compared With an Approved Asthma Treatment (BDA With HFA Propellant) in Participants With Asthma

Phase: N/A Priority: Normal
NCT ID: NCT06502366 Org: User:
Start: 07/22/24 End: 03/03/26 Due: 03/03/27

Evaluation of Crestor® (Rosuvastatin) in Daily Practice

Phase: N/A Priority: Normal
NCT ID: NCT00837083 Org: User:
Start: 01/31/07 End: 10/31/07 Due: 10/31/08

A Clinical Trial to Compare Efficacy and Tolerability of Fulvestrant 250mg, 250mg (Plus 250mg Loading Regimen) and 500mg

Phase: N/A Priority: Normal
NCT ID: NCT00305448 Org: User:
Start: 03/31/06 End: 02/29/12 Due: 02/28/13

A Study on Patients With Chronic Kidney Disease (CKD) to Assess Treatment Experience and Patterns, Effect of the Treatment, Patient Outcomes and Patient Quality of Life

Phase: N/A Priority: Normal
NCT ID: NCT04034992 Org: User:
Start: 09/11/19 End: 06/30/23 Due: 06/30/24

A Multicenter, Randomized, Double-Blind Parallel-Group, Placebo-Controlled Efficacy Study Comparing 4 Weeks of Treatment With Esomeprazole 20 mg Once Daily to Placebo qd for the Resolution of Upper Abdominal Pain in Patients With Symptomatic Gastroesophageal Reflux Disease (sGERD)

Phase: N/A Priority: Normal
NCT ID: NCT00626535 Org: User:
Start: 03/31/03 End: 02/29/04 Due: 02/28/05

Evaluation Study of a Management Strategy for Gastroesophageal Reflux Disease (GERD)

Phase: N/A Priority: Normal
NCT ID: NCT00842387 Org: User:
Start: 01/31/09 End: 12/31/09 Due: 12/31/10

Comparison of Bone Mineral Loss in Prostate Cancer Patients Who is Receiving GnRH Agonist and -Plus Anti-androgen Agent

Phase: N/A Priority: Normal
NCT ID: NCT01303692 Org: User:
Start: 04/30/11 End: 02/28/14 Due: 02/28/15

Outcomes in UK ACS Patients Prescribed Ticagrelor

Phase: N/A Priority: Normal
NCT ID: NCT03058601 Org: User:
Start: 01/04/16 End: 03/31/16 Due: 03/31/17